Document Detail


High perinatal survival in monoamniotic twins managed by prophylactic sulindac, intensive ultrasound surveillance, and Cesarean delivery at 32 weeks' gestation.
MedLine Citation:
PMID:  17001748     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Increased perinatal mortality in monoamniotic twin pregnancies is attributed to cord accidents in utero and at delivery. We evaluated the following parameters in monoamniotic pregnancies: (1) the incidence of cord entanglement; (2) the effect of sulindac on amniotic fluid volume and stability of fetal lie; and (3) the perinatal outcome with our current management paradigm. METHODS: This is a retrospective review of monoamniotic pregnancies of >or=20 weeks' gestation managed with serial ultrasound surveillance, medical amnioreduction and elective Cesarean delivery at 32 weeks' gestation. Mean amniotic fluid index (AFI) and change in AFI in monoamniotic pregnancies managed with oral sulindac was compared with 40 gestation-matched monochorionic-diamniotic controls. RESULTS: Among 44 monoamniotic pregnancies, 20 with two live structurally normal twins at 20 weeks' gestation satisfied the inclusion criteria. All fetuses survived to 28 days postnatally despite early prenatal cord entanglement in all but one case. Whereas AFI remained stable throughout gestation in the controls, the AFI fell in those patients on sulindac from a mean value of 21.0 cm (95% CI, 18.5-23.6 cm) at 20 weeks to a mean of 12.4 cm (95% CI, 10.1-14.6 cm) at 32 weeks (ANOVA P across gestation = 0.001) but mainly remained within normal limits. Fetal lie was stabilized in 11/20 cases in the monoamniotic group compared with 13/40 in the control group (P < 0.0001). CONCLUSIONS: Cord entanglement appears unpreventable, as it typically occurs in early pregnancy. Sulindac therapy reduces AFI, leads to more stable fetal lie, and may prevent intrauterine death by diminishing the risk of constricting cords that are already entangled. Perinatal survival in monoamniotic pregnancies managed by a regime of sulindac from 20 weeks' gestation, close ultrasound surveillance and elective abdominal delivery at 32 weeks' gestation seems empirically higher than that in the literature.
Authors:
L Pasquini; R C Wimalasundera; A Fichera; O Barigye; L Chappell; N M Fisk
Related Documents :
15503278 - Hemodynamic changes with phenotype reversal during pregnancy in twin-twin transfusion s...
2333908 - Fetal disruptions: assessment of frequency, heterogeneity, and embryologic mechanisms i...
19372698 - Extreme polycythemia in recipient twin with twin-to-twin transfusion syndrome: a case r...
19626028 - Medical and ethical considerations in twin pregnancies discordant for serious cardiac d...
22067258 - Body mass index at 11-13 weeks' gestation and pregnancy complications.
9447368 - Dihydralazine or ketanserin for severe hypertension in pregnancy? preliminary results.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology     Volume:  28     ISSN:  0960-7692     ISO Abbreviation:  Ultrasound Obstet Gynecol     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-02     Completed Date:  2007-08-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9108340     Medline TA:  Ultrasound Obstet Gynecol     Country:  England    
Other Details:
Languages:  eng     Pagination:  681-7     Citation Subset:  IM    
Copyright Information:
Copyright 2006 ISUOG. Published by John Wiley & Sons, Ltd.
Affiliation:
Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, London, UK. l.pasquini@imperial.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amniocentesis
Amnion
Cesarean Section*
Female
Fetal Death / prevention & control
Gestational Age
Humans
Infant, Newborn
Pregnancy
Pregnancy Outcome
Pregnancy, Multiple
Prenatal Care / methods
Retrospective Studies
Sulindac / therapeutic use*
Twins, Monozygotic*
Ultrasonography, Prenatal / methods*
Chemical
Reg. No./Substance:
38194-50-2/Sulindac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesi...
Next Document:  Comparison of alternative methods of collection of service use data for the economic evaluation of h...